<?xml version="1.0" encoding="UTF-8"?>
<p id="par0255">IFN therapy is commonly used when a specific drug or vaccine is not available to treat some virus infection. The type 1 IFN is usually known as a participant to the mammalian host defense against virus infection [
 <xref rid="bib0665" ref-type="bibr">133</xref>]. The use of recombinant IFN inducers or IFN alone have been appointed as a treatment option for MERS, supported by the fact that coronaviruses are able to suppress IFN, making it necessary to increase this response [
 <xref rid="bib0670" ref-type="bibr">134</xref>,
 <xref rid="bib0675" ref-type="bibr">135</xref>]. A recent study 
 <italic>in vitro</italic> with Vero E6 cells has reported that after pretreatment with IFN-I, a decrease in viral protein and SARS-CoV-2 replication was observed [
 <xref rid="bib0680" ref-type="bibr">136</xref>].
</p>
